Evaluating crisaborole as a treatment option for atopic dermatitis.

Authors:
Vignesh Ramachandran
Vignesh Ramachandran
Infectious Diseases Laboratory
India
Abigail Cline
Abigail Cline
Medical College of Georgia
Augusta | United States
Steven R Feldman
Steven R Feldman
Center for Dermatology Research
United States
Lindsay C Strowd
Lindsay C Strowd
Wake Forest University School of Medicine
United States

Expert Opin Pharmacother 2019 Jun 19;20(9):1057-1063. Epub 2019 Apr 19.

d Department of Dermatology , Wake Forest School of Medicine , Winston-Salem , NC , USA.

Introduction: Atopic dermatitis (AD) is a chronic and recurrent disease presenting with eczematous lesions and pruritus. It impacts patient and family quality of life, increases morbidity, and accounts for large health-care expenditures. Although nonpharmacologic, topical, and systemic treatments exist, management of AD remains challenging due to limited treatment options. Crisaborole is a topical small molecule inhibitor of phosphodiesterase 4 (PDE4), recently approved for the treatment of AD in the United States. Areas covered: The authors review crisaborole in the management of AD based on Phase II, Phase III, and post-marketing studies. Pharmacologic properties such as chemistry, pharmacokinetics, pharmacodynamics and metabolism are discussed. A PubMed systematic review was augmented with Google Scholar searches via keyword, Medical Subject Headings (MeSH), and Boolean operation searches. Expert opinion: Crisaborole showed modest efficacy in short-term trials, but head-to-head trials with topical corticosteroids and tacrolimus are needed to assess its clinical utility. Since crisaborole is non-steroidal, it may reduce the need for topical corticosteroids and address steroid phobia. However, it is likely to suffer from the same factors contributing to intentional non-adherence in topicals: dissatisfaction with efficacy and inconvenience.

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2019.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2019.1604688DOI Listing
June 2019
8 Reads

Publication Analysis

Top Keywords

topical corticosteroids
8
atopic dermatitis
8
corticosteroids tacrolimus
4
areas covered
4
covered authors
4
states areas
4
treatment united
4
tacrolimus needed
4
united states
4
authors review
4
phase phase
4
phase iii
4
based phase
4
management based
4
review crisaborole
4
crisaborole management
4
approved treatment
4
pde4 approved
4
crisaborole topical
4
utility crisaborole
4

References

(Supplied by CrossRef)

Similar Publications